Endologix acquires PQ Bypass, developer of percutaneous femoral-popliteal bypass for PAD
Click Here to Manage Email Alerts
Endologix announced it completed the acquisition of PQ Bypass, a medical technology company that developed a platform for percutaneous femoral-popliteal bypass for severe peripheral artery disease.
PQ Bypass’ platform (Detour) for percutaneous femoral-popliteal bypass received a Breakthrough Device Designation from the FDA.
As Healio previously reported, percutaneous femoral-popliteal bypass was associated with high rates of patency and low rates of complications at 24 months in patients with severe PAD.
According to a press release, the platform is currently being studied in a U.S. and European clinical trial, DETOUR2.
In 2017, PQ Bypass received conditional approval of its investigational device exemption from the FDA to begin the first-ever pivotal trial for percutaneous femoropopliteal bypass.
“The acquisition of PQ Bypass is a seminal moment in Endologix’s history, building upon our leadership in the treatment of abdominal aortic aneurysm to champion disruptive technologies for the treatment of vascular disease,” Richard Mott, CEO and chairman of Endologix, said in the release. “We intend to actively pursue new and innovative vascular technologies that are clinically relevant to surgeons, hospitals and patients, with a commitment to world-class medical education, clinical research and excellent procedural outcomes.”
Collapse
Click Here to Manage Email Alerts